New eczema drug candidate HXN5003 begins first human safety trial
NCT ID NCT07549750
First seen May 05, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This early-phase study tests whether a single dose of HXN5003 is safe and tolerable in 28 healthy adults aged 18-55. Researchers will monitor side effects, vital signs, and how the drug moves through the body. This is a first step toward developing a treatment for atopic dermatitis (eczema), but no direct benefit is expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Veritus Research
Bayswater, Victoria, 3153, Australia
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.